Key clinical point: Hepatectomy is beneficial in patients with ≤3 hepatocellular carcinomas (HCC) and no or Child-Pugh (CP) class A cirrhosis, with the long-term results being comparable to those in patients with single HCC.
Major finding: The overall survival was significantly different between patients with Barcelona Clinic Liver Cancer (BCLC) stages A1 and A2 ( P = .0118), A2 and A3 ( P = .0013), and B1 and B2 ( P = .0050) but not between stages A3 and B1 ( P = .4742). CP class B cirrhosis was an independent prognostic factor for overall survival.
Study details: This single-center retrospective study included 1088 patients who underwent hepatectomy for BCLC stage 0 (n = 88), A (n = 750), or B (n = 250) HCC, with stages A and B categorized into A1 (single nodule 2-5 cm or ≤3 nodules ≤3 cm), A2 (single nodule 5-10 cm), A3 (single nodule ≥10 cm), B1 (2-3 nodules >3 cm), and B2 (≥4 nodules).
Disclosures: No information on funding source was available. The authors declared no conflicts of interest.
Source: Orimo T et al. Hepatectomy is beneficial in select patients with multiple hepatocellular carcinomas. Ann Surg Oncol. 2022 (Sep 13). Doi: 10.1245/s10434-022-12495-z
